Fairvalue-Calculator Fairvalue-Calculator
EN DE

Idorsia Ltd (IDIA) Fair Value & Analysis

Healthcare · CH · Market cap CHF 1.1B

PriceCHF 5.94
Fair ValueCHF 26.28
Upside+342.8%
Quality95/100
Evidence: Low Range CHF 15.89 – CHF 33.78

Fair value as of: Jun 24, 2026

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Idorsia Ltd (IDIA) currently trades at CHF 5.94, while our model-based Fair Value estimate is CHF 26.28 — implying the stock looks roughly 342.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple s…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Idorsia Ltd (IDIA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of CHF 26.28 versus a price of CHF 5.94 — about +343% (undervalued). Model-based estimate, not financial advice.
What is the fair value of IDIA?
Our 21-model fair value for Idorsia Ltd is CHF 26.28 (as of Jun 24, 2026), built from audited fundamentals. The current price is CHF 5.94.
What is the quality score of IDIA?
Idorsia Ltd has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.